CLINICAL TRIALS PROFILE FOR SITAGLIPTIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for SITAGLIPTIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00087516 ↗ | Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-06-01 | The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00095056 ↗ | An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-10-01 | The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function). |
| NCT00103857 ↗ | MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-03-17 | The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes). |
| NCT00127192 ↗ | A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2005-07-01 | The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00305604 ↗ | Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-03-08 | To evaluate the effect of treatment with sitagliptin compared to placebo in elderly patients with type 2 diabetes mellitus who have poor glycemic control with diet and exercise. |
| NCT00337610 ↗ | Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-01 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy. |
| NCT00350779 ↗ | Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-12 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SITAGLIPTIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for SITAGLIPTIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for SITAGLIPTIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for SITAGLIPTIN HYDROCHLORIDE
Sponsor Name
